Mylan Pharmaceuticals Inc., a Viatris company, is voluntarily recalling one batch of Insulin Glargine (Insulin glargine-yfgn) Injection, 100 units/mL (U-100), 3 mL prefilled pens which are ...

Mylan also makes the distinction that this isn’t the Semglee brand pen, but unbranded Insulin Glargine-yfgn pens. This covers batch No. BF21002895, expiration August 2023.

Mylan also makes the distinction that this isn’t the Semglee brand pen, but unbranded Insulin Glargine-yfgn pens. This covers batch No. BF21002895, expiration August 2023.

Kirsty is biosimiler to Novolog. It is a rapid-acting human insulin analog indicated to improve glycemic control in adults ...

In addition, “the use of biosimilar insulin, which was first approved in 2015, increased from 2.6% in 2017 to 8.2% in 2020 of total insulin treatment visits,” while “the total number of ...

Mylan Pharmaceuticals has issued a voluntary recall of one batch of its 100 units/mL insulin glargine injection pens due to the potential for missing labels, according to a press release from the ...

Patients were randomly assigned (1:1) to receive their insulin using pen devices or vials and syringes. The study was conducted in accordance with the Declaration of Helsinki. [16] ...

Lannett previously said that subject dosing has been completed in the pivotal clinical trial of Lannett/HEC's biosimilar insulin glargine and no serious adverse events were reported. The company ...